A Phase 1/Phase 2 open-label study to evaluate the safety, tolerability, and efficacy of a single intravenous administration of SAR444836 in adult participants with phenylketonuria

Trial Identifier: DFI17545
Sponsor: Sanofi
Start Date: August 2023
Primary Completion Date: April 2030
Study Completion Date: April 2030
Condition: Metabolic Disorder

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Argentina, Buenos Aires Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina, 1199
BRAZIL, Rio Grande do Sul Porto Alegre, Rio Grande do Sul, BRAZIL, 90035903
ISRAEL Tel HaShomer, ISRAEL, 52621
Turkey ANKARA, Turkey, 06560
UNITED STATES, California San Francisco, California, UNITED STATES, 94143
UNITED STATES, Colorado Aurora, Colorado, UNITED STATES, 80045
UNITED STATES, Florida Gainesville, Florida, UNITED STATES, 32610
UNITED STATES, Ohio Cleveland, Ohio, UNITED STATES, 44106
UNITED STATES, Pennsylvania Pittsburgh, Pennsylvania, UNITED STATES, 15224-1334
UNITED STATES, South Carolina Charleston, South Carolina, UNITED STATES, 29425
UNITED STATES, Texas Houston, Texas, UNITED STATES, 77030